High On-Treatment Platelet Reactivity as a Tool for Risk Stratification in STEMI Patients

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Individual response variability to antiplatelet agents is well-documented.
• High on-treatment platelet reactivity (HPR) identifies patients at increased risk for major adverse cardiovascular events (MACE).
• Understanding HPR is crucial for optimizing antiplatelet therapy in cardiovascular patients.

Purpose of the Study:

• To investigate the long-term (5-year) risk of MACE in ST-elevation myocardial infarction (STEMI) patients treated with dual antiplatelet therapy (DAPT).
• To assess the association between HPR and atherosclerosis markers.
• To evaluate different methods for HPR assessment in STEMI patients.

Main Methods:

• Prospective study of STEMI patients treated with DAPT (ticagrelor and aspirin).
• Utilized thromboelastography, total thrombus formation analysis system, and vasodilator-stimulated phosphoprotein phosphorylation assay (VASP) for HPR assessment.
• Analyzed laboratory parameters, including lipid profiles and C-reactive protein, during hospitalization and correlated them with HPR and MACE.

Main Results:

• STEMI patients with HPR on DAPT demonstrated a significantly higher risk of MACE over 5 years.
• HPR was found to be associated with atherosclerosis, indicated by specific lipid profile parameters.
• Correlations between laboratory parameters and HPR were identified.

Conclusions:

• High on-treatment platelet reactivity (HPR) is a significant independent predictor of long-term MACE in STEMI patients.
• Elevated C-reactive protein and atherogenic lipid profiles potentiate the risk associated with HPR.
• Standardizing HPR assessment is essential for personalized antiplatelet therapy and improved patient outcomes.